Payload Information

General Information of This Payload

Payload ID	PAY0YLEVE
Name	Pseudomonas exotoxin PE40
Synonyms	Pseudomonas exotoxin PE40 Click to Show/Hide
Target(s)	Eukaryotic elongation factor 2 (EEF2)	Target Info

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	1400	ng/mL	OVCAR-2 cells	Ovarian carcinoma	CVCL_3941	[1]
Half Maximal Inhibitory Concentration (IC50)	1400	ng/mL	HuT 102 cells	Mycosis fungoides	CVCL_3526	[1]
Half Maximal Inhibitory Concentration (IC50)	>2000	ng/mL	NIH3T3 cells	Normal	CVCL_0594	[1]
Half Maximal Inhibitory Concentration (IC50)	610	ng/mL	KB cells	Human papillomavirus-related endocervical adenocarcinoma	CVCL_0372	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

hD7-1 (VL-VH)-PE40 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.00 pM	Positive PSMA expression (PSMA+++/++)
Method Description	The immunotoxins hD7-1 (VL-VH)-PE40 was tested for specific cytotoxic activity against PSMA-positive LNCaP and C4-2 cells.
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	55.00 pM	Positive PSMA expression (PSMA+++/++)
Method Description	The immunotoxins hD7-1 (VL-VH)-PE40 was tested for specific cytotoxic activity against PSMA-positive LNCaP and C4-2 cells.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

References

Ref 1	Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988 Jul 5;263(19):9470-5.
Ref 2	In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer. Anticancer Res. 2018 Jan;38(1):61-69. doi: 10.21873/anticanres.12192.